In this podcast, you will hear a keynote presentation from the 2019 Clinical Research as a Care Option (CRAACO) conference. Dr Laura Esserman, the architect behind the I-SPY 2 TRIALTM has achieved remarkable progress with this clinical trial in improving the outcomes of early stage, breast cancer for patients who are at high risk for early recurrence. I-SPY 2 is also impacting far beyond breast cancer by increasing efficiencies that promise to accelerate the development and delivery of more effective therapies for other cancer types and a range of other diseases. This would not be possible without the integration of care and research. In this keynote session, hear this surgeon’s view on the future of integrating care and research.
Laura Esserman, MD, MBA, Director, UCSF Carol Franc Buck Breast Cancer Center; Alfred A. de Lorimier Endowed Chair in General Surgery; Professor of Surgery and Radiology, UCSF
The 2020 CRAACO conference will be taking place April 27-28 in Raleigh, NC. Learn more about it here.